Anti-PD-1 immunotherapy in advanced esophageal squamous cell carcinoma: A long-awaited breakthrough finally arrives
Journal
Journal of the Formosan Medical Association
Journal Volume
119
Journal Issue
2
Pages
565-568
Date Issued
2020
Author(s)
Other Subjects
immunological antineoplastic agent; nivolumab; pembrolizumab; programmed death 1 receptor; programmed death 1 receptor antibody; unclassified drug; monoclonal antibody; PDCD1 protein, human; programmed death 1 receptor; advanced cancer; cancer immunotherapy; clinical practice; clinical trial (topic); esophageal squamous cell carcinoma; human; phase 3 clinical trial (topic); Short Survey; cell cycle checkpoint; drug effect; esophageal squamous cell carcinoma; esophagus tumor; immunotherapy; procedures; randomized controlled trial (topic); Antibodies, Monoclonal, Humanized; Cell Cycle Checkpoints; Clinical Trials, Phase III as Topic; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Immunotherapy; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic
Publisher
Elsevier B.V.
Type
journal article